3 years on, FDA still evaluating Qdenga dengue vaccine application
MANILA, Philippines — The proposed new generation anti-dengue vaccine remains under review by the Food and Drug Administration (FDA) three years after it applied for registration, according to Malacañang. Citing a statement from the Department of Health (DOH), Palace press officer Claire Castro said the application of Japanese pharmaceutical company Takeda for the certificate of product
Original Source
Read the full article at Newsinfo →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.